Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America

Overview

Journal Am J Respir Crit Care Med

Specialty Critical Care

Date 2019 Oct 2

PMID 31573350

Citations 1281

Authors

Joshua P Metlay

Grant W Waterer

Ann C Long

Antonio Anzueto

Jan Brozek

Kristina Crothers

Laura A Cooley

Nathan C Dean

Michael J Fine

Scott A Flanders

Marie R Griffin

Mark L Metersky

Daniel M Musher

Marcos I Restrepo

Cynthia G Whitney

Affiliations

Soon will be listed here.

Abstract

This document provides evidence-based clinical practice guidelines on the management of adult patients with community-acquired pneumonia. A multidisciplinary panel conducted pragmatic systematic reviews of the relevant research and applied Grading of Recommendations, Assessment, Development, and Evaluation methodology for clinical recommendations. The panel addressed 16 specific areas for recommendations spanning questions of diagnostic testing, determination of site of care, selection of initial empiric antibiotic therapy, and subsequent management decisions. Although some recommendations remain unchanged from the 2007 guideline, the availability of results from new therapeutic trials and epidemiological investigations led to revised recommendations for empiric treatment strategies and additional management decisions. The panel formulated and provided the rationale for recommendations on selected diagnostic and treatment strategies for adult patients with community-acquired pneumonia.

Citing Articles

Antimicrobial strategies of lower respiratory tract infections in immunocompromised patients based on metagenomic next-generation sequencing: a retrospective study.

Meng B, Liu H, Wu Q, Qu L, Mao C, Yang F BMC Infect Dis. 2025; 25(1):360.

PMID: 40087607 DOI: 10.1186/s12879-025-10753-5.

Deep vein thrombosis in severe community-acquired pneumonia patients undergoing thromboprophylaxis: Prevalence, risk factors, and outcome.

Cui N, Wang J, Feng X, Zhang L, Yang Y Thromb J. 2025; 23(1):23.

PMID: 40075406 PMC: 11905501. DOI: 10.1186/s12959-025-00706-y.

Cavitary Pneumonia Causes in the Arid Landscapes of Southern Arizona.

El Kurdi R, Nayar K, Gotway M, Blair J, Nagarakanti S Am J Med Open. 2025; 13:100090.

PMID: 40061083 PMC: 11889622. DOI: 10.1016/j.ajmo.2025.100090.

Best practices for guideline development in Critical Care.

Kawano-Dourado L, Pitre T, Zeraatkar D, Guyatt G Crit Care Sci. 2025; 37:e20250372.

PMID: 40053017 PMC: 11869816. DOI: 10.62675/2965-2774.20250372.

Microbiological Diagnostic Performance and Clinical Effect of Metagenomic Next-Generation Sequencing for the Detection of Immunocompromised Patients With Community-Acquired Pneumonia.

Zheng H, Peng P, Wang S, Zhang B, Yang L, Wang Y Infect Drug Resist. 2025; 18:1223-1236.

PMID: 40052063 PMC: 11883178. DOI: 10.2147/IDR.S462358.

References

Falcone M, Russo A, Giannella M, Cangemi R, Scarpellini M, Bertazzoni G . Individualizing risk of multidrug-resistant pathogens in community-onset pneumonia. PLoS One. 2015; 10(4):e0119528. PMC: 4393134. DOI: 10.1371/journal.pone.0119528. View

English M, Fredericks C, Milanesio N, Rohowsky N, Xu Z, Jenta T . Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies. Antimicrob Agents Chemother. 2012; 56(4):2037-47. PMC: 3318370. DOI: 10.1128/AAC.05596-11. View

Blum C, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I . Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015; 385(9977):1511-8. DOI: 10.1016/S0140-6736(14)62447-8. View

Piso R, Iven-Koller D, Koller M, Bassetti S . The routine use of urinary pneumococcal antigen test in hospitalised patients with community acquired pneumonia has limited impact for adjustment of antibiotic treatment. Swiss Med Wkly. 2012; 142:w13679. DOI: 10.4414/smw.2012.13679. View

Uyeki T . Preventing and controlling influenza with available interventions. N Engl J Med. 2014; 370(9):789-91. PMC: 6636328. DOI: 10.1056/NEJMp1400034. View

Metersky M, Masterton R, Lode H, File Jr T, Babinchak T . Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis. 2012; 16(5):e321-31. DOI: 10.1016/j.ijid.2012.01.003. View

Chalmers J, Taylor J, Mandal P, Choudhury G, Singanayagam A, Akram A . Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis. 2011; 53(6):503-11. DOI: 10.1093/cid/cir463. View

Uematsu H, Hashimoto H, Iwamoto T, Horiguchi H, Yasunaga H . Impact of guideline-concordant microbiological testing on outcomes of pneumonia. Int J Qual Health Care. 2013; 26(1):100-7. DOI: 10.1093/intqhc/mzt078. View

van Rensburg D, Perng R, Mitha I, Bester A, Kasumba J, Wu R . Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. Antimicrob Agents Chemother. 2010; 54(10):4098-106. PMC: 2944601. DOI: 10.1128/AAC.00295-10. View

10.

Lonks J, Garau J, Gomez L, Xercavins M, Ochoa de Echaguen A, Gareen I . Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis. 2002; 35(5):556-64. DOI: 10.1086/341978. View

11.

Kalil A, Metersky M, Klompas M, Muscedere J, Sweeney D, Palmer L . Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016; 63(5):e61-e111. PMC: 4981759. DOI: 10.1093/cid/ciw353. View

12.

El-Solh A, Pietrantoni C, Bhat A, Aquilina A, Okada M, Grover V . Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med. 2003; 167(12):1650-4. DOI: 10.1164/rccm.200212-1543OC. View

13.

Cesar L, Gonzalez C, Calia F . Bacteriologic flora of aspiration-induced pulmonary infections. Arch Intern Med. 1975; 135(5):711-4. DOI: 10.1001/archinte.135.5.711. View

14.

Metlay J, Kapoor W, Fine M . Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA. 1997; 278(17):1440-5. View

15.

Horita N, Otsuka T, Haranaga S, Namkoong H, Miki M, Miyashita N . Adjunctive Systemic Corticosteroids for Hospitalized Community-Acquired Pneumonia: Systematic Review and Meta-Analysis 2015 Update. Sci Rep. 2015; 5:14061. PMC: 4571641. DOI: 10.1038/srep14061. View

16.

Wiesner B, Lehtonen L . Twice daily dosing of erythromycin acistrate in the treatment of acute bronchitis and pneumonia. Arzneimittelforschung. 1993; 43(9):1014-7. View

17.

Torre-Cisneros J, Natera C, Mesa F, Trikic M, Rodriguez-Bano J . Clinical predictors of methicillin-resistant Staphylococcus aureus in nosocomial and healthcare-associated pneumonia: a multicenter, matched case-control study. Eur J Clin Microbiol Infect Dis. 2017; 37(1):51-56. DOI: 10.1007/s10096-017-3100-y. View

18.

Guyatt G, Oxman A, Kunz R, Atkins D, Brozek J, Vist G . GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011; 64(4):395-400. DOI: 10.1016/j.jclinepi.2010.09.012. View

19.

Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J . Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015; 313(7):677-86. DOI: 10.1001/jama.2015.88. View

20.

Salvarezza C, Mingrone H, Fachinelli H, Kijanczuk S . Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia. J Antimicrob Chemother. 1998; 41 Suppl B:75-80. DOI: 10.1093/jac/41.suppl_2.75. View